Πλοήγηση ανά Συγγραφέα "Diamantopoulos P.T., Pappa V., Symeonidis A., Kotsianidis I., Galanopoulos A., Papadaki H., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Kotsopoulou M., Repousis P., Dimou M., Solomou E., Pontikoglou C., Kyriakakis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kourakli A., Panayiotidis P., Viniou N.-A."

Αποτελέσματα 1-1 από 1

Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry

Diamantopoulos P.T., Pappa V., Symeonidis A., Kotsianidis I., Galanopoulos A., Papadaki H., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Kotsopoulou M., Repousis P., Dimou M., Solomou E., Pontikoglou C., Kyriakakis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kourakli A., Panayiotidis P., Viniou N.-A. (2020)

Background: Hypomethylating agents have altered the prognosis of myelodysplastic syndrome (MDS) so that long-term survival is now a feasible treatment goal. Patients and Methods: We analyzed data from patients with MDS ...